Tuesday, November 17, 2026

FDA Approves Mimrylo (rusfertide) for the Treatment of Polycythemia Vera

Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.




  • Mimrylo, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)
  • Mimrylo Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve Fatigue
  • Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32

Mimrylo is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1

“For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Current treatments, such as phlebotomy, leave a significant gap for too many patients and can pose challenges to daily life and routines. The approval of Mimrylo offers clinicians and patients a novel, first-in-class therapy that targets erythrocytosis, which drives excess red blood cell production in PV. The strength and consistency of the VERIFY data give me real confidence in Mimrylo’s potential to advance how we treat PV in everyday practice and to maintain hematocrit control.”

Uncontrolled Hematocrit is a Challenge in the Treatment of PV

Affecting approximately 90,000 people in the U.S., PV is characterized by the overproduction of red blood cells (erythrocytosis), leading to elevated hematocrit which can increase blood viscosity, or thickness.2,3 This has the potential to result in life-threatening thrombotic events, including stroke, deep vein thrombosis and pulmonary embolism.4 Maintaining hematocrit levels consistently below 45% can prevent thrombotic events and alleviate burdensome symptoms, including severe fatigue, pruritus (itching), difficulty concentrating and night sweats.4 An estimated 78% of patients still experience uncontrolled hematocrit with current standard of care, including phlebotomy and cytoreductive therapies.5 Patients with PV experiencing uncontrolled hematocrit have a four times higher risk of cardiovascular death or major cardiovascular events.4

“People living with PV often experience complex and invisible symptoms, from extreme fatigue to the emotional strain of living with a chronic blood cancer,” said Kapila Viges, Chief Executive Officer, MPN Research Foundation. “At the same time, we know that every patient’s experience with PV is different, underscoring the need to continue to listen closely to the community to understand what matters most. There remains a need for treatments that better address these daily challenges. This meaningful approval reflects important progress and brings forward a new treatment option in a disease where patients have long needed innovation and more choices. We are encouraged by Mimrylo’s potential to help patients meet their treatment goals.”

Mimrylo is a First-In-Class Treatment Option for Adults with PV

The approval was supported by data from the global randomized Phase 3 VERIFY study (NCT05210790) that included 293 patients with PV, showing that Mimrylo met all efficacy endpoints and demonstrated a favorable safety profile. In the study, patients receiving Mimrylo plus current standard of care demonstrated a higher response rate compared to placebo plus current standard of care. This included hematocrit control, a reduction in the need for phlebotomy and improvement in fatigue as measured by PROMIS Fatigue Short Form 8a.

Mimrylo was generally well-tolerated through 52 weeks of treatment in the VERIFY trial. The most common treatment-emergent adverse events in Mimrylo-treated patients were injection site reactions and anemia. Learn more about the Phase 3 data results here.

“The approval of Mimrylo underscores the strength of Takeda’s late-stage pipeline and our focus on developing genuinely differentiated therapies for patients who are urgently waiting for new options,” said Julie Kim, President and Chief Executive Officer, Takeda. “We are at an important inflection point as we prepare to deliver three new medicines, which have the potential to drive our future growth and are a reflection of our commitment to advancing innovation that doesn’t just add to the treatment landscape, but reshapes it. We are grateful to the patients, care partners, advocates and investigators who helped make this approval possible.”

The open-label extension of the VERIFY trial is ongoing and Takeda will share further findings at upcoming medical conferences. Takeda is working with regulators outside of the U.S. to potentially bring Mimrylo to more patients worldwide.

Ref: https://en.wikipedia.org/wiki/Rusfertide

Monday, November 16, 2026

FDA Approves Ambelvist (gadoquatrane) Low-Dose Contrast Agent for Magnetic Resonance Imaging


Bayer announced  the U.S. Food and Drug Administration (FDA) approval of  gadoquatrane, a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) under the brand name Ambelvist™. The product is indicated for contrast-enhanced magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system (CNS) and non-CNS body regions in adult and pediatric patients, including term neonates. Gadoquatrane is a next-generation mGBCA with a novel tetrameric structure and high relaxivity (a measure of signal enhancement).




  • Gadoquatrane from Bayer receives FDA approval for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions
  • Gadoquatrane becomes the lowest-dose macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) approved in the U.S., with a recommended dose of 0.01 mmol/kg actual body weight, corresponding to 0.04 mmol Gd/kg body weight
  • Approval is supported by data from the Phase III QUANTI clinical studies, which demonstrated efficacy at a fraction of the dose compared to mGBCAs dosed at 0.1 mmol Gd/kg body weight
  • Gadoquatrane received its first approval in Japan in March 2026, further submissions to health authorities worldwide are ongoing to secure marketing authorization in additional markets

With this approval, gadoquatrane becomes the lowest dose mGBCA in the U.S. It has a recommended dose of 0.01 mmol/kg actual body weight (which corresponds to 0.04 mmol Gd/kg body weight), representing 60% less Gd compared to mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight and 20% less Gd compared to gadopiclenol dosed at 0.05 mmol Gd/kg body weight.

There is a rising need for medical imaging, driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases. Contrast-enhanced MRI is a medical imaging examination often used by clinicians to gain insight into what’s happening in the human body and can play an important role in detecting abnormalities, monitoring disease progression and informing treatment decisions. For some adults and children with chronic diseases or conditions that require close, long-term monitoring – such as multiple sclerosis, other neurological or spinal conditions as well as different types of cancer – regular, repeat administrations may be required.

“I often rely on contrast-enhanced MRI exams to inform clinical decision making,” said Dr. Christopher Hancock, Director of Neuroradiology at HALO Diagnostics Desert Cities, USA, and an investigator for the QUANTI clinical studies. “With this approval, we now have an additional option that can help deliver contrast-enhanced images at the lowest macrocyclic GBCA dose, reducing gadolinium exposure while preserving the clinical information we often need.”

“Bayer is a leader in radiology and has played a pioneering role in MRI contrast agent development, having launched the first gadolinium-based contrast agent in 1988,” said Dr. Konstanze Diefenbach, Head of Radiology R&D at Bayer’s Pharmaceuticals Division. “With gadoquatrane – a next generation high-relaxivity, low-dose MRI contrast agent demonstrating high stability – we continue driving advances for patients and their treating physicians. Reducing patients’ lifetime exposure to gadolinium is an important consideration and reflects the growing clinical guidance to use the lowest gadolinium dose necessary to adequately image patients.”

Gadoquatrane received its first approval in Japan in March 2026, and Bayer has submitted applications for marketing authorization in additional markets around the world, including the EU and China, with more to follow.

Key Clinical Trial Findings
The FDA’s approval is based on the global pivotal Phase III QUANTI clinical studies, which evaluated the efficacy and safety of gadoquatrane in adult and pediatric patients, including term neonates, undergoing contrast-enhanced MRI. Key findings demonstrated:

· Increased lesion visualization with the combined pre-contrast and post-contrast MRI sets with the decreased Gd dose in gadoquatrane compared with only pre-contrast MRI images.

· Visualization scores and number of lesions identified per blinded independent reader for gadoquatrane dosed at 0.01 mmol/kg body weight (which corresponds to 0.04 mmol Gd/kg body weight) were similar to mGBCAs with a Gd content of 0.1 mmol Gd/kg body weight.

· Use in children is supported by evidence from adequate and well-controlled studies of gadoquatrane in adults, with additional pharmacokinetic and safety data from the pediatric study, including 93 patients aged 28 days to less than 18 years who received one 0.01mmol/kg dose and underwent MRI of any body region.

About gadoquatrane
Gadoquatrane is Bayer’s extracellular macrocyclic contrast agent for contrast enhancement in MRI. This low-dose gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity.

The compound has been approved under the brand name Ambelvist™ in Japan in March 2026 and in the U.S. in June 2026. It has not been approved in any other jurisdiction. Bayer has submitted applications for marketing authorization of gadoquatrane in additional markets around the world.

About MRI
MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection and monitoring of diseases. MRI contrast agents commonly contain gadolinium. For 2024, it is estimated that over 60 million doses of gadolinium-based contrast agents were administered worldwide. Cumulatively, since 1988, more than 900 million GBCA doses have been delivered globally.

About Radiology at Bayer
Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions. In 2025, Bayer’s radiology products generated €2.2 billion in sales. Bayer continues to advance research and innovation in medical imaging, including in molecular imaging and other promising fields.

https://en.wikipedia.org/wiki/Gadoquatrane

Saturday, November 14, 2026

FDA Approves Utebzi (tebipenem pivoxil) for Adults with Complicated Urinary Tract Infections

GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO)   announced  the US Food and Drug Administration (FDA)  approval of  Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisa, caused by certain susceptible pathogensb in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This approval is a result of GSK’s development and exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.4






  • First and only oral carbapenem antibiotic approved in the US
  • Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1
  • More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3

There are more than 3 million cases of cUTI in the US annually and treatment failure impacts up to 34% of patients.2,3 Often caused by multidrug-resistant pathogens,5 these infections account for over $6 billion per year in healthcare costs.6 Carbapenems are the standard treatment for severe or resistant infections, but until now have only been available through intravenous administration7, increasing hospital resource use and reducing patients’ quality of life.8 Tebipenem pivoxil offers the potential for an effective oral alternative taken outside of a hospital setting.

Tony Wood, Chief Scientific Officer, GSK, said: “With antibiotic resistance continuing to rise, patients and healthcare professionals need new treatment options. The approval of Utebzi provides the first and only oral carbapenem antibiotic for appropriate adults with complicated UTIs, a solution that could help reduce reliance on hospital-based intravenous care and support efforts to address resistant infections.”

Dr. Bilal Chughtai, Chief of Urology at Plainview Hospital, Northwell Health and Associate Professor of Urology at the Zucker School of Medicine at Hofstra/Northwell, said: “For patients with complicated urinary tract infections (cUTIs) and their caregivers, this approval is a major milestone as today’s standard of care places a serious burden on them and hospitals. A new effective oral treatment offering an alternative option to intravenous care has the potential to enable more treatment in the outpatient settings with the ambition to improve their experience.”

Esther Rajavelu, President and Chief Executive Officer, Spero Therapeutics added: “The FDA approval of tebipenem pivoxil marks the culmination of more than a decade of dedication from our team, partners, and, most importantly, the patients who placed their trust in this program. We are proud to reach this important milestone. Through our partnership with GSK, we look forward to this much-needed oral treatment option reaching cUTI patients to help reduce the burden of the disease.”

This approval is supported by positive results from the PIVOT-PO phase III trial, which demonstrated non-inferiority of tebipenem pivoxil compared to intravenous imipenem-cilastatin in hospitalised patients with cUTI, including pyelonephritis, based on the overall response (composite of clinical cure plus microbiological eradication) at the test of cure visit. Tebipenem pivoxil (oral, 600 mg) achieved a 58.5% overall success rate (261/446 participants) compared to 60.2% overall success rate (291/483 participants) for imipenem-cilastatin (intravenous, 500 mg) (adjusted treatment difference: −1.3%; 95% CI: −7.5%, 4.8%).

The safety profile of tebipenem pivoxil was generally similar to that of imipenem-cilastatin and other carbapenem antibiotics. The most frequently reported adverse events (in ≥3% of patients) were diarrhoea and headache; these events were all mild or moderate and non-serious.1

Tebipenem pivoxil is anticipated to be made available to US patients by the end of 2026. With this approval, GSK builds on recent advances in its growing anti-infectives portfolio.

This approval confirms the successful and productive collaboration between GSK and Spero Therapeutics. The development of tebipenem pivoxil has been supported in part with federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201800015C and HHSO100201300011C.

a Pyelonephritis is a specific type of UTI that has travelled up the urinary tract to infect one or both kidneys.

b Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae species complex, Klebsiella oxytoca, and Enterococcus faecalis.

About tebipenem pivoxil

Tebipenem pivoxil was developed in collaboration with Spero Therapeutics4 for the treatment of cUTIs, including pyelonephritis. In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics for the development and commercialisation in all markets, except certain Asian territories. Under this agreement, GSK sub-licensed back to Spero Therapeutics the rights and responsibility to conduct certain development work, including the PIVOT-PO phase III study. The sponsorship of the New Drug Application has been transferred to GSK. As part of the license agreement, tebipenem pivoxil has received Qualified Infectious Disease Product and Fast Track designations from the US FDA.

About the PIVOT-PO trial

The PIVOT-PO trial was a global, randomised, double-blind, pivotal, non-inferiority (NI margin: -10%) phase III trial evaluating the potential of oral tebipenem pivoxil compared to IV imipenem-cilastatin, in hospitalised adult patients with complicated urinary tract infections, including acute pyelonephritis. Patients were randomised 1:1 to receive tebipenem pivoxil (600 mg) orally every six hours, or imipenem-cilastatin (500 mg) IV every six hours, for a total of seven to ten days. Dose adjustments were made for patients with reduced renal function. Matching placebos were used to maintain blinding. The primary efficacy endpoint was composite response (combined per-patient clinical cure and microbiological response) at the test-of-cure visit (about 17 days from first dose administration of study drug) in patients with qualifying pathogens susceptible to imipenem. The trial enrolled a total of 1,690 patients, with randomisation stratified by age, baseline diagnosis (cUTI or acute pyelonephritis), and the presence or absence of urinary tract instrumentation. For further details on the trial, refer to clinicaltrials.gov identifier NCT0605984


https://en.wikipedia.org/wiki/Tebipenem_pivoxil



Thursday, November 12, 2026

FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA)   approval of  Lipfendra (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lipfendra is a novel macrocyclic peptide and is the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C, also known as bad cholesterol.




  • At week 24 in the CORALreef Lipids and CORALreef HeFH trials, Lipfendra significantly reduced LDL-C by a placebo-adjusted 56% and 59%, respectively
  • Lipfendra is a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors

“By harnessing the innovative science of PCSK9 inhibitors and novel macrocyclic peptide technology, Lipfendra was designed to significantly lower LDL-C in the form of a convenient once-daily pill,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “This is a pivotal moment as we bring the first U.S. FDA-approved oral PCSK9 inhibitor to adults with high LDL-C, offering patients an important new option. We’re proud of our work with regulators on this rigorous and efficient review process.”

The approval is based on two Phase 3 trials from the CORALreef clinical program: CORALreef Lipids and CORALreef HeFH. In CORALreef Lipids, Lipfendra reduced LDL-C by 56% compared to placebo at week 24. A 60% decrease from baseline in LDL-C was observed with Lipfendra when biologically impossible baseline LDL-C values were removed according to revised data handling rules (post-hoc). In CORALreef HeFH, Lipfendra reduced LDL-C by 59% at week 24 compared to placebo. Results from these Phase 3 trials showed treatment with Lipfendra resulted in reductions across other atherogenic lipoproteins associated with atherosclerotic cardiovascular disease (ASCVD) risk including non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB). The safety profile of Lipfendra in CORALreef Lipids was similar to placebo. In CORALreef HeFH, the most common adverse reactions in adults with HeFH treated with Lipfendra that occurred at higher frequencies compared to placebo were diarrhea (Lipfendra 7%, placebo 2%) and dizziness (Lipfendra 9%, placebo 4%). In both trials, similar proportions of Lipfendra-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. For additional information on results from the CORALreef trials, see “Clinical data supporting FDA approval” below.

“High LDL-C is a major risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death globally,” said Dr. Ann Marie Navar, a lead author of the CORALreef Lipids study and associate professor of medicine in the Division of Cardiology at UT Southwestern Medical Center. “In two Phase 3 trials, Lipfendra led to impressive reductions in LDL-C. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering.”

An ongoing clinical trial is studying the effect of Lipfendra on cardiovascular morbidity and mortality. It is not yet known if Lipfendra can reduce the risk of cardiovascular morbidity and mortality.

“One of the greatest opportunities to help manage the risk of ASCVD lies in the timely identification and appropriate treatment of risk factors, such as LDL-C,” said Katherine Wilemon, CEO of the Family Heart Foundation. “We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering.”

Clinical data supporting FDA approval

Lipfendra was approved based on results from two pivotal Phase 3 trials from the CORALreef clinical trial program:

  • At week 24, in the CORALreef Lipids trial, treatment with Lipfendra resulted in:
    • A statistically significant and clinically meaningful reduction in LDL-C of 56% compared to placebo at week 24 (95% CI: -61, -51; p<0.001), with a reduction from baseline (primary endpoint) in LDL-C of 57% for Lipfendra compared to an increase of 3% for placebo;
    • When LDL-C values ≤0 were removed according to revised data handling rules (post-hoc), a statistically significant and clinically meaningful reduction in LDL-C of 60% for Lipfendra compared to an increase of 3% for placebo at week 24 (95% CI: -62, -57%).
    • Statistically significant reductions in secondary endpoints from baseline to week 24 compared to an increase of 3% for placebo:
      • 54% mean reduction in non-HDL-C for Lipfendra;
      • 50% mean reduction in ApoB for Lipfendra.
  • At week 24, in the CORALreef HeFH trial, treatment with Lipfendra resulted in:
    • A statistically significant and clinically meaningful reduction in LDL-C of 59% compared to placebo (95% CI: -66, -53; p<0.001), with a reduction from baseline (primary endpoint) in LDL-C of 58% for Lipfendra compared to an increase of 3% for placebo;
    • Statistically significant reductions in secondary endpoints from baseline to week 24 compared to an increase of 2% for placebo:
      • 52% mean reduction in non-HDL-C for Lipfendra;
      • 48% mean reduction in ApoB for Lipfendra.

In CORALreef Lipids, the frequencies of adverse reactions in adults with hypercholesterolemia were similar between those treated with Lipfendra and those receiving placebo. Similar proportions of Lipfendra-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. In CORALreef HeFH, the most common adverse reactions in adults with HeFH treated with Lipfendra that occurred at higher frequencies compared to placebo were diarrhea (Lipfendra 7%, placebo 2%) and dizziness (Lipfendra 9%, placebo 4%). Similar proportions of Lipfendra-treated patients and placebo-treated patients discontinued treatment because of an adverse reaction. The safety profile observed in adults with HeFH in CORALreef HeFH was otherwise generally consistent with that observed in adults with hypercholesterolemia in CORALreef Lipids.

About CORALreef Lipids and HeFH

CORALreef Lipids (NCT05952856) was a Phase 3, multicenter, double-blind, randomized, placebo-controlled study in which 2,904 patients with hypercholesterolemia (including those with and without HeFH) and a history of a major ASCVD event or increased risk for development of a first major ASCVD event were randomized in a 2:1 ratio to receive Lipfendra 20 mg orally once daily (n=1,935) or placebo (n=969) for 52 weeks. Patients required additional LDL-C reduction despite stable lipid-lowering treatment with moderate- or high-intensity statins (unless statin intolerance was documented) with or without other lipid-modifying therapy. Patients taking PCSK9 inhibitors were excluded from the trial. The primary efficacy outcome measure was the mean percent change from baseline to week 24 in LDL-C.

CORALreef HeFH (NCT05952869) was a Phase 3, multicenter, double-blind, randomized, placebo-controlled study in which 303 patients with HeFH were randomized in a 2:1 ratio to receive Lipfendra 20 mg orally once daily (n=202) or placebo (n=101) for 52 weeks. Patients required additional LDL-C reduction despite stable lipid-lowering treatment with moderate- or high-intensity statins, with or without other lipid-modifying therapy. The diagnosis of HeFH was made by clinical criteria or genotyping. The primary efficacy outcome measure was the mean percent change from baseline to week 24 in LDL-C.

https://en.wikipedia.org/wiki/Enlicitide_chloride

Wednesday, November 11, 2026

Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care

IN CONTINUATION OF MY UPDATE ON semaglutide and tirzepatide 

In a recent study published in the journal Communications Medicine, a group of researchers examined associations between initiation of tirzepatide or semaglutide and incident neuropsychiatric diagnoses in adults with obesity, compared with other weight-loss treatments, with separate analyses for individuals with and without type 2 diabetes.

Background

Currently, obesity affects more than 650 million adults globally, with implications for physical and mental well-being. People with obesity are more likely to suffer from psychiatric conditions, including anxiety and depression, than people without obesity. Moreover, mental illness can increase the chances of developing obesity. Newer incretin-based medications like semaglutide and tirzepatide have changed obesity treatment by producing substantial weight loss, but their effects on neuropsychiatric health remain uncertain in routine clinical practice. 

About the study

Researchers conducted a retrospective cohort study using de-identified electronic health records from the TriNetX United States Collaborative Network between January 2020 and November 2025. Adults meeting the study’s obesity criteria, who newly initiated tirzepatide or semaglutide, were identified and compared with matched individuals who started naltrexone-bupropion, phentermine, or phentermine-topiramate. The study included two separate analyses based on whether or not the participants had type 2 diabetes, and bariatric surgery recipients and a non-pharmacological weight-loss cohort were also evaluated as contextual comparison groups.

To increase comparability between treatment groups, propensity score matching was performed using demographic features, body mass index (BMI), glycated hemoglobin (HbA1c), medical history, co-existing treatments, healthcare utilization, and results of laboratory investigations. Patients with type 1 diabetes, prior bariatric surgery, history of organ transplantation, human immunodeficiency virus (HIV) infection, and end-stage renal disease were not included. Patients were monitored for a maximum of 24 months from treatment initiation until the initial diagnosis of a neuropsychiatric outcome, death, loss to follow-up, or end of study.

The primary outcome was a new diagnosis of anxiety disorder. Secondary outcomes included diagnoses of depression, mood disorder, insomnia, broadly defined cognitive deficits, nerve disorders, peripheral neuropathy, and substance-related disorders. Hazard ratios with 95% confidence intervals (CIs) were obtained using Cox proportional hazards models, adjusted for possible confounders, and various sensitivity analyses were also performed.

Study results

Before matching, individuals initiating incretin-based therapies differed considerably from comparator groups, particularly regarding psychiatric illnesses and psychotropic medication use. After matching on propensity scores, the groups had very similar baseline demographic characteristics, cardiometabolic health issues, laboratory measures, and health care use, allowing for more reliable comparisons between the treatment groups.

 

Individuals receiving semaglutide and tirzepatide generally had lower hazards of several recorded neuropsychiatric diagnoses when compared to bariatric surgery recipients.

Among individuals with obesity and type 2 diabetes, both medications were associated with lower hazards of anxiety disorders, broadly defined cognitive deficits, mood disorders, and depression. Similar results were seen for individuals without type 2 diabetes, but the neurological outcomes were less consistent between the groups. 

Semaglutide was associated with a higher hazard of nerve disorders in participants without diabetes, while tirzepatide showed lower hazards of substance-related disorders and peripheral neuropathy compared with bariatric surgery. The negative control analyses did not find any clinically meaningful differences, providing some reassurance about the analytical approach.

Compared with naltrexone-bupropion, semaglutide was associated with lower hazards of anxiety disorders, depression, cognitive deficits, and insomnia in adults with type 2 diabetes. Tirzepatide also showed lower hazards of anxiety disorders, depression, mood disorders, and cognitive deficits within this group.

Similar reductions were observed among adults without diabetes, indicating that both medications were consistently associated with lower rates of several recorded psychiatric diagnoses than this comparator.

Among adults without type 2 diabetes, a direct comparison between tirzepatide and semaglutide showed that tirzepatide was associated with higher hazards of anxiety disorders and insomnia than semaglutide, while no consistent differences were observed for most neurological outcomes after statistical adjustment. However, the authors noted that absolute and relative estimates differed for anxiety and insomnia in this head-to-head comparison, so these small differences should be interpreted cautiously.

Absolute risk differences indicated larger reductions in anxiety disorders among individuals with type 2 diabetes than among those without diabetes when tirzepatide or semaglutide was compared with naltrexone-bupropion.

Sensitivity analyses generally supported the primary findings. Per-protocol and as-treated analyses showed similar directions of association for anxiety and depression, although the strength of some associations varied depending on treatment persistence. Lower use of psychiatric medications, particularly selective serotonin reuptake inhibitors (SSRIs), was also observed among incretin-based therapy recipients compared with matched comparator groups.

Subgroup analyses suggested that the associations were generally consistent across age, BMI, and clinical characteristics, with some stronger associations observed among older adults and individuals with severe obesity.

Exploratory analyses generally showed greater reductions in body weight and HbA1c over 24 months in the incretin-based therapy groups than in the conventional anti-obesity medication groups, although some comparisons varied by diabetes status and outcome measure.

Additional sensitivity analyses using stricter outcome definitions and alternative cohort criteria yielded findings that were directionally similar, though some estimates became less precise due to smaller sample sizes. Importantly, cognitive findings were sensitive to outcome definition, and the broad cognitive endpoint included codes that could reflect acute or transient altered mental status rather than dementia or progressive cognitive decline.

Conclusion

The findings suggest that initiation of tirzepatide and semaglutide is associated with different neuropsychiatric outcome patterns depending on the comparator treatment and the presence of type 2 diabetes. Compared with naltrexone-bupropion, both medications were generally associated with lower hazards of anxiety and depression. In contrast, tirzepatide showed higher hazards of anxiety and insomnia than semaglutide among adults without type 2 diabetes.

These findings provide clinicians and patients with important real-world evidence to inform treatment decisions, while underscoring the need for continued patient monitoring. However, the results should not be interpreted as evidence that these medications prevent dementia, progressive cognitive decline, or psychiatric disease, because the study relied on diagnosis codes and remains vulnerable to residual confounding and misclassification.

In addition, as this study was observational, prospective studies with standardized neuropsychiatric assessments are needed to confirm these associations. Further research is needed to understand how these medications may influence mental health outcomes across different patient populations.




Study links semaglutide and tirzepatide to fewer anxiety and depression diagnoses in obesity care

Tuesday, November 10, 2026

Bacteria's 'mix-and-match' code could create new cancer-fighting drugs

A team of researchers at the University of Warwick and Monash University has solved a puzzle that has stumped drug developers for decades: how bacteria naturally create multiple versions of powerful cancer therapies. The breakthrough could accelerate the development of new treatments for hard-to-treat cancers.

Harnessing bacterial enzymes to create drug variants, a strategy known as combinatorial biosynthesis, has long been a goal for scientists. But without understanding how these enzymes interact, progress has stalled.

 

Skeletal formula of romidepsin

Romidepsin, sold under the brand name Istodax

https://en.wikipedia.org/wiki/Romidepsin

Published in Nature Communications, the researchers have finally revealed how bacterial enzymes communicate and work together to assemble a family of related anticancer compounds. This family includes romidepsin (Istodax), a clinically approved blood cancer treatment. By understanding this "mix-and-match" process and replicating the principle in the lab, the researchers have established an approach to designing new therapies.

How the enzymes coordinate

"For decades, we've known that bacteria can naturally produce multiple versions of powerful anticancer drugs, yet we had no idea how they achieved this," said first author Dr. Munro Passmore, a research fellow in the Department of Chemistry at the University of Warwick.

"This work finally cracks that code. We've identified how the different enzymes communicate and cooperate to produce these drug variants, something that has eluded researchers because the system is so elegantly economical. It's the breakthrough we needed to actually engineer these drugs ourselves."

The team's analysis reveals that small molecular regions, termed "docking domains," act as connectors between the core drug assembly machinery and the variable component-building enzymes. Crucially, these docking domains use a conserved connection point that is compatible with multiple different enzyme partners, a feature that explains how bacteria generate structural diversity while keeping their drugs precise and effective.

 

A blueprint for new candidates

The work also traces how these drug-producing systems evolve naturally. The researchers found that the newly discovered compound likely evolved from a related drug-producing system through gene duplications and recombinations.

Greg Challis, Monash Warwick Alliance professor of sustainable chemistry at the University of Warwick and Monash University, concluded, "This research gives us a blueprint to do what nature does, but better and faster. By reverse-engineering nature's evolutionary logic, we can now design synthetic pathways that generate new anticancer drug candidates with properties optimized for clinical use, such as superior potency, improved selectivity and fewer side effects.

"Our immediate goal is to build an expanded library of candidates for various cancers where new treatments are urgently needed. This discovery is moving us from understanding how the systems work to building new ones."

 

 




Bacteria's 'mix-and-match' code could create new cancer-fighting drugs

Monday, November 9, 2026

AbbVie bags EC approval for Maviret to treat acute HCV infection

AbbVie announced that the European Commission approved Maviret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy for the treatment of acute hepatitis C virus (HCV) infection in adults and children aged 3 years and older. With this approval, Maviret is now the only treatment approved in the European Union for both acute and chronic HCV infection.





"More than 12 million people in Europe live with hepatitis C, underscoring the need for earlier treatment," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "Today's European Commission approval of Maviret for acute hepatitis C infection enables earlier intervention, aiming to help more people access curative therapy at the time of diagnosis, while accelerating progress toward the goal of eliminating hepatitis C as a public health threat."


HCV is a highly infectious blood-borne disease that often goes undetected because people may not show symptoms. While HCV is curable, many people remain undiagnosed. If left untreated, HCV can progress to severe liver complications, including cirrhosis and end-stage liver disease. Current clinical guidance supports treating nearly all people with acute or chronic HCV infection.


"People living with HCV infection frequently face delayed treatment, leading to loss to care and onward transmission," said Massimo Puoti, MD, director of the Infectious Diseases Department at Niguarda Hospital in Milan, Italy. "With this approval, healthcare professionals across the European Union now have an approved treatment option to treat patients at the earliest stage of infection, supporting prompt intervention and helping to reduce transmission, disease progression, and long-term complications for people living with hepatitis C."


Globally, HCV poses a substantial health and economic burden, with over 200,000 deaths each year from liver cancer. People living with HCV are up to 17 times more likely to develop liver cancer than those unaffected.

The approval was supported by data from the Phase 3, multicenter, single-arm prospective study evaluating the safety and efficacy of Maviret eight-week treatment regimen in patients with acute HCV infection.

The study results showed Maviret to be a highly efficacious treatment for people with acute HCV. The majority of the adverse events reported were mild or moderate in severity. The most common adverse events were fatigue, diarrhea, headache, and asthenia.AbbVie continues to collaborate with global regulatory authorities to support access to Maviret for people living with acute HCV infection. Maviret is approved in the United States, Saudi Arabia, New Zealand, Canada, Taiwan, Australia and Argentina for the treatment of acute and chronic HCV infection in adults and children aged 3 years and older.

The overall safety profile observed in the M20-350 study was similar to that observed in patients with chronic HCV infection. No serious adverse reactions or adverse reactions leading to treatment discontinuation that were judged as treatment-related were observed among patients with acute HCV infection. The most commonly reported adverse reactions were fatigue (3%), asthenia (2%), headache (2%), and diarrhea (2%).

https://en.wikipedia.org/wiki/Glecaprevir/pibrentasvir

Friday, November 6, 2026

Sanofi announces approvals for Wayrilz and Cenrifki

The Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing and manufacturing authorization to French pharma major Sanofi’s (Euronext: SAN) Wayrilz (rilzabrutinib), a novel oral reversible Bruton’s tyrosine kinase inhibitor (BTKi).

The drug is authorized for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic. Wayrilz can help address the underlying causes of the disease, through multi-immune modulation, targeting key pathways across the immune system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Tolebrutinib


https://en.wikipedia.org/wiki/Tolebrutinib
Wayrilz (rilzabrutinib)

https://en.wikipedia.org/wiki/Rilzabrutinib





Thursday, November 5, 2026

Tea Plants' Secret Weapon Against Disease: The Power of Sakuranetin


Tea plants use sakuranetin as a natural antifungal shield against anthracnose, offering hope for greener farming Tea, one of the world's most cherished beverages, may have a powerful natural defense system hidden within its leaves

Scientists from the Zhejiang Academy of Agricultural Sciences have uncovered a molecular mechanism that enables certain tea plants to resist anthracnose—a destructive fungal disease that causes significant losses in tea plantations worldwide.

Their research reveals that a naturally occurring compound called sakuranetin (SAK) acts as a potent antifungal shield, helping resistant tea varieties stop infections before they spread.

The findings, published in Horticulture Research, provide fresh insights into how tea plants defend themselves and could open new avenues for sustainable tea cultivation. 


Understanding Tea Plant Resistance


Anthracnose, caused by the fungus Colletotrichum camelliae, is among the most damaging diseases affecting tea crops. The pathogen spreads through wind and rain, infecting leaves and reducing both yield and quality.

Current control methods rely heavily on synthetic fungicides, raising concerns about environmental impact and chemical residues in a beverage consumed globally as a direct infusion.

Although tea plants naturally produce defensive compounds such as catechins and caffeine, researchers wanted to understand how the plant activates additional defenses after a fungal attack.

To investigate, the team compared two tea cultivars with contrasting disease responses: 'Zijuan', which is naturally resistant to anthracnose, and 'Longjing43', a widely cultivated but more susceptible variety.

The Science Behind Sakuranetin

The researchers discovered that when C. camelliae attacks, the resistant cultivar 'Zijuan' rapidly produces high levels of sakuranetin, a plant defense molecule known as a phytoalexin. This compound creates a hostile environment for the fungus, significantly restricting its growth.

Laboratory tests revealed that sakuranetin displayed stronger antifungal activity against C. camelliae than epigallocatechin gallate (EGCG), one of tea's most abundant and well-known catechins.

The key to this defense lies in an enzyme called naringenin 7-O-methyltransferase (NOMT), produced by the CsNOMT gene. The enzyme converts a flavonoid precursor, naringenin, into sakuranetin, effectively equipping the plant with a powerful chemical weapon.

Researchers observed that infected 'Zijuan' leaves accumulated substantial amounts of sakuranetin, whereas the susceptible cultivar 'Longjing43' produced very little.

A Molecular Relay Activates the Defense

The study uncovered an intricate defense pathway controlled by the plant hormone jasmonic acid (JA), a key regulator of immune responses in plants.

When the fungus invades, JA signaling becomes activated. This, in turn, stimulates a transcription factor called CsMYC2.1, which binds directly to the promoter region of the CsNOMT gene and switches it on.
Once activated, CsNOMT boosts sakuranetin production, creating a rapid chemical barrier against fungal invasion.

Researchers describe this process as a molecular relay:

Pathogen attack → JA signaling → CsMYC2.1 activation → CsNOMT expression → Sakuranetin production → Antifungal defense

This cascade was considerably stronger in 'Zijuan' than in 'Longjing43', explaining why the resistant cultivar is better protected from anthracnose.

Experiments Confirm the Protective Role

To confirm the importance of this pathway, scientists altered the expression of the CsNOMT gene.

When CsNOMT was silenced, sakuranetin levels dropped and plants became more vulnerable to anthracnose infection. Conversely, increasing CsNOMT expression elevated sakuranetin production and significantly reduced disease symptoms.

These experiments demonstrated that disease resistance is not determined by the presence of a single gene alone, but by how efficiently the plant activates its entire defense network when challenged by a pathogen.

Implications for Sustainable Tea Farming

The discovery has important implications for the future of tea cultivation.

The genes CsNOMT and CsMYC2.1 could serve as molecular markers, allowing breeders to identify and develop anthracnose-resistant tea varieties more quickly through marker-assisted breeding.

In addition, sakuranetin itself may provide a blueprint for developing natural biopesticides or plant defense stimulants that reduce reliance on synthetic fungicides.

Such approaches could help tea growers improve crop resilience while addressing growing concerns over environmental sustainability and chemical residues.

Beyond Tea: A Broader View of Plant Immunity

The findings also broaden scientists' understanding of plant immunity. While phytoalexin-based defenses have been extensively studied in crops such as rice and model plants, this research demonstrates that woody perennial crops like tea also rely on inducible chemical defenses to combat disease.

By linking hormone signaling, gene regulation, metabolite production, and disease resistance into a single framework, the study offers one of the clearest pictures yet of how tea plants mount a sophisticated defense against fungal attack.

For tea lovers around the world, this hidden molecular shield may one day help ensure healthier crops, more sustainable farming practices, and a more resilient future for one of the world's most beloved beverages.

Ref : JA–CsMYC2.1–CsNOMT–sakuranetin module contributes to differential anthracnose resistance in Camellia sinensis - (https://academic.oup.com/hr/article/13/5/uhag022/8444634?login=false)




https://en.wikipedia.org/wiki/Sakuranetin

More: